Um alle Funktionen dieser Seite zu nutzen, aktivieren Sie bitte die Cookies in Ihrem Browser.
Mit einem my.bionity.com-Account haben Sie immer alles im Überblick - und können sich Ihre eigene Website und Ihren individuellen Newsletter konfigurieren.
- Meine Merkliste
- Meine gespeicherte Suche
- Meine gespeicherten Themen
- Meine Newsletter
1.896 Aktuelle Fachpublikationen von Future Medicinerss
07.06.2013 | Maria Lucia Corrêa-Giannella; Ubiratan F Machado, Pharmacogenomics, 2013
Pharmacogenomics , June 2013, Vol. 14, No. 8, Pages 847-850.
07.06.2013 | Ana Alfirevic; Daniel F Carr; Fabio Miyajima; Sudeep Pushpakom; Laura Sutton; Andrea L Jorgensen; Munir ..., Pharmacogenomics, 2013
The Wolfson Centre for Personalised Medicine is part of the Institute of Translational Medicine at the University of Liverpool (Liverpool, UK). It houses a multidisciplinary team of personalized medicine researchers engaged in collaborative research with partners across the globe. The primary ...
07.06.2013 | Fabrice André; Joseph Ciccolini; Jean-Philippe Spano; Frédérique Penault-Llorca; Nicolas Mounier; Gilles ..., Pharmacogenomics, 2013
Current advances in the biology of cancer and emergence of new tools for genome analysis have opened clinical perspectives in oncology, generally termed as ‘personalized medicine’. This broad term must encompass previous well-proven strategies, such as pharmacogenetics- and ...
07.06.2013 | James J Chen; Wei-Jiun Lin; Hung-Chia Chen, Pharmacogenomics, 2013
Pharmacogenomics examines how the benefits and adverse effects of a drug vary among patients in a target population by analyzing genomic profiles of individual patients. Personalized medicine prescribes specific therapeutics that best suit an individual patient. Much current research focuses ...
07.06.2013 | Marc Via; Haig Tcheurekdjian; Esteban González Burchard, Pharmacogenomics, 2013
Researchers have identified thousands of loci involved in complex traits and drug response. However, in most cases they only explain a small proportion of the heritability of the trait. Among different strategies conducted to identify this ‘missing heritability’, here we illustrate the ...
07.06.2013 | Grace M Kuo; Kelly C Lee; Joseph D Ma, Pharmacogenomics, 2013
Aim: This study evaluated the implementation and outcomes of a pharmacogenomics education program among pharmacists. Materials & methods: Continuing education lectures were presented at local, state and national pharmacy conferences. Results: Six hundred and seventy three pharmacist ...
06.06.2013 | Kyle B Brothers; Matthew J Westbrook; M Frances Wright; John A Myers; Daniel R Morrison; Jennifer L Madi ..., Personalized Medicine, 2013
Aim: In this study, we sought to assess patient awareness and perceptions of an opt-out biorepository. Materials & methods: We conducted exit interviews with adult patients and parents of pediatric patients having their blood drawn as part of their clinical care at Vanderbilt University ...
06.06.2013 | Reem Alsolami; Samantha JL Knight; Anna Schuh, Personalized Medicine, 2013
Chronic lymphocytic leukemia (CLL) is low-grade lymphoma of mature B cells and it is considered to be the most common type of hematological malignancy in the western world. CLL is characterized by a chronically relapsing course and clinical and biological heterogeneity. Many patients do not ...
06.06.2013 | Kristin Pothier; Gary Gustavsen, Personalized Medicine, 2013
We are entering an era of unprecedented complexity in personalized medicine. Therapeutic targets, biomarker detection technologies, regulatory and reimbursement pathways, and commercialization strategies have all reached new levels of intricacy. These complexities are occurring in the context ...
06.06.2013 | Personalized Medicine, 2013
Personalized Medicine , June 2013, Vol. 10, No. 4, Pages 325-327.